167 related articles for article (PubMed ID: 32502322)
1. Diffuse MIST1 expression and decreased α1,4-linked N-acetylglucosamine (αGlcNAc) glycosylation on MUC6 are distinct hallmarks for gastric neoplasms showing oxyntic gland differentiation.
Yamada S; Yamanoi K; Sato Y; Nakayama J
Histopathology; 2020 Sep; 77(3):413-422. PubMed ID: 32502322
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of gastric gland mucin-specific glycan α1,4-linked N-acetylglucosamine on its scaffold mucin 6 is associated with malignant potential of pyloric gland adenoma of the stomach.
Yamanoi K; Sekine S; Higuchi K; Kushima R; Nakayama J
Histopathology; 2015 Dec; 67(6):898-904. PubMed ID: 25929994
[TBL] [Abstract][Full Text] [Related]
3. Decreased alpha-1,4-linked N-acetylglucosamine glycosylation in biliary tract cancer progression from biliary intraepithelial neoplasia to invasive adenocarcinoma.
Okumura M; Yamanoi K; Uehara T; Nakayama J
Cancer Sci; 2020 Dec; 111(12):4629-4635. PubMed ID: 33020993
[TBL] [Abstract][Full Text] [Related]
4. Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach.
Shiratsu K; Higuchi K; Nakayama J
Cancer Sci; 2014 Jan; 105(1):126-33. PubMed ID: 24138592
[TBL] [Abstract][Full Text] [Related]
5. Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.
Ohya A; Yamanoi K; Shimojo H; Fujii C; Nakayama J
Cancer Sci; 2017 Sep; 108(9):1897-1902. PubMed ID: 28685935
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of TFF2 and decreased αGlcNAc glycosylation are malignant biomarkers of pyloric gland adenoma of the duodenum.
Yamanoi K; Fujii C; Nakayama A; Matsuura N; Takatori Y; Kato M; Yahagi N; Nakayama J
Sci Rep; 2023 Dec; 13(1):21641. PubMed ID: 38062108
[TBL] [Abstract][Full Text] [Related]
7. Reduced αGlcNAc glycosylation on gastric gland mucin is a biomarker of malignant potential for gastric cancer, Barrett's adenocarcinoma, and pancreatic cancer.
Yamanoi K; Nakayama J
Histochem Cell Biol; 2018 Jun; 149(6):569-575. PubMed ID: 29658052
[TBL] [Abstract][Full Text] [Related]
8. Reduced gland mucin-specific O-glycan in gastric atrophy: A possible risk factor for differentiated-type adenocarcinoma of the stomach.
Yamada S; Okamura T; Kobayashi S; Tanaka E; Nakayama J
J Gastroenterol Hepatol; 2015 Oct; 30(10):1478-84. PubMed ID: 25967588
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation of MUC6 by α1,4-linked N-acetylglucosamine enhances suppression of pancreatic cancer malignancy.
Yuki A; Fujii C; Yamanoi K; Matoba H; Harumiya S; Kawakubo M; Nakayama J
Cancer Sci; 2022 Feb; 113(2):576-586. PubMed ID: 34808019
[TBL] [Abstract][Full Text] [Related]
10. MUC6 expression is a preferable prognostic marker for invasive mucinous adenocarcinoma of the lung.
Yamanoi K; Fujii C; Yuzuriha H; Kumazawa M; Shimoda M; Emoto K; Asamura H; Nakayama J
Histochem Cell Biol; 2022 Jun; 157(6):671-684. PubMed ID: 35353213
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of αGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma--a possible biomarker to predict the malignant potential of Barrett's oesophagus.
Iwaya Y; Hasebe O; Koide N; Kitahara K; Suga T; Shinji A; Muraki T; Yokosawa S; Yamada S; Arakura N; Tanaka E; Nakayama J
Histopathology; 2014 Mar; 64(4):536-46. PubMed ID: 24117499
[TBL] [Abstract][Full Text] [Related]
12. Gastric gland mucin-specific O-glycan expression decreases as tumor cells progress from lobular endocervical gland hyperplasia to cervical mucinous carcinoma, gastric type.
Yamanoi K; Ishii K; Tsukamoto M; Asaka S; Nakayama J
Virchows Arch; 2018 Sep; 473(3):305-311. PubMed ID: 29845361
[TBL] [Abstract][Full Text] [Related]
13. Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix.
Asaka S; Nakajima T; Momose M; Miyamoto T; Uehara T; Ota H
Virchows Arch; 2019 Jan; 474(1):79-86. PubMed ID: 30324235
[TBL] [Abstract][Full Text] [Related]
14. α1,4-Linked N-acetylglucosamine suppresses gastric cancer development by inhibiting Mucin-1-mediated signaling.
Fujii C; Harumiya S; Sato Y; Kawakubo M; Matoba H; Nakayama J
Cancer Sci; 2022 Nov; 113(11):3852-3863. PubMed ID: 35959971
[TBL] [Abstract][Full Text] [Related]
15. Decreased Gastric Gland Mucin-specific
Ohya A; Matoba H; Fujinaga Y; Nakayama J
Acta Histochem Cytochem; 2021 Aug; 54(4):115-122. PubMed ID: 34511650
[TBL] [Abstract][Full Text] [Related]
16. Gastric adenocarcinoma of the fundic gland type shares common genetic and phenotypic features with pyloric gland adenoma.
Kushima R; Sekine S; Matsubara A; Taniguchi H; Ikegami M; Tsuda H
Pathol Int; 2013 Jun; 63(6):318-25. PubMed ID: 23782334
[TBL] [Abstract][Full Text] [Related]
17. αGlcNAc and its catalyst α4GnT are diagnostic and prognostic markers in uterine cervical tumor, gastric type.
Ida K; Yamanoi K; Asaka S; Takeuchi H; Miyamoto T; Shiozawa T; Nakayama J
Sci Rep; 2019 Sep; 9(1):13043. PubMed ID: 31506488
[TBL] [Abstract][Full Text] [Related]
18. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma.
Ueyama H; Yao T; Nakashima Y; Hirakawa K; Oshiro Y; Hirahashi M; Iwashita A; Watanabe S
Am J Surg Pathol; 2010 May; 34(5):609-19. PubMed ID: 20410811
[TBL] [Abstract][Full Text] [Related]
19. Gastric adenocarcinoma of fundic gland mucosa type localized in the submucosa: A case report.
Uchida A; Ozawa M; Ueda Y; Murai Y; Nishimura Y; Ishimatsu H; Okouchi Y; Ishiguro K; Hamada Y; Sasamoto R; Watanabe M; Sano N; Miyamoto R; Inagawa S; Kikuchi K
Medicine (Baltimore); 2018 Sep; 97(37):e12341. PubMed ID: 30212986
[TBL] [Abstract][Full Text] [Related]
20. Pyloric gland adenoma: an entity distinct from gastric foveolar type adenoma.
Chen ZM; Scudiere JR; Abraham SC; Montgomery E
Am J Surg Pathol; 2009 Feb; 33(2):186-93. PubMed ID: 18830123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
